RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target

Melanoma Research

Volumn 20, Issue 1, 2010, Pages 35-42

  Thamm, Douglas H ^a   Huelsmeyer, Michael K ^b   Mitzey, Ann M ^b   Qurollo, Barbara ^a   Rose, Barbara J ^a   Kurzman, Ilene D ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer; Dog; Insulin like growth factor; Polymerase chain reaction; Tyrosine kinase

Indexed keywords

ABELSON KINASE; ADW 742; AXL ENZYME; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOCAL ADHESION KINASE 1; JANUS KINASE 1; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ANTAGONISM; MELANOMA; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL LINE, TUMOR; DOG DISEASES; DOGS; HUMANS; MELANOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 75749123942     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328331ca86     Document Type: Article

References (58)

1. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-979.
2. Withrow SJ. Cancer of the oral cavity. In:Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd ed. Philadelphia: Saunders; 2001, pp. 305-317.
3. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006; 126: 945-947.
4. Economou MA, All-Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O, Seregard S. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005; 46:4372-4375.
5. Lacal PM, Ruffini F, Pagani E, D'Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 2005; 27:1625-1632.
6. Gordon-Thomson C, Jones J, Mason RS, Moore GP. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005; 15:21-28.
7. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004; 40:858-880.
8. Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models for drug development. In: Teicher BA, Andrews PA, editors. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa, NJ: Humana Press; 2004, pp. 259-284.
9. Tanaka K, Nagayama Y, Nakano T, Takamura N, Namba H, Fukada S, et al. Expression profile of receptor-type protein tyrosine kinase genes in the human thyroid. Endocrinology 1998; 139:852-858.
10. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006; 55:433-442.
11. Whitley EM, Bird AC, Zucker KE, Wolfe LG. Modulation by canine interferongamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 1995; 15:923-929.
12. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5:221-230.
13. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005; 11:1563-1571.
14. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004; 3:527-535.
15. Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, Sorenmo KU. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med 2001; 15:131-135.
16. Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, Macewen EG. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci 2006; 81:76-86.
17. Tsou A-P, Wu K-M, Tsen T-Y, Chi C-W, Chiu J-H, Lui W-Y, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998; 50:331-340.
18. Craven RJ, Xu L, Weiner TM, Fridell Y-W, Dent GA, Srivastava S, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995; 60:791-797.
19. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metsatases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155:1271-1279.
20. Lin W-c, Li AF-Y, Chi C-W, Chung W-W, Kung H-J, Wu C-W. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res 1999; 5:1745-1751.
21. Chen W-S, Kung H-J, Yang W-K, Lin W-c. Comparative tyrosine-kinase profiles in colorectal cancers: enhnced arg expressed in carcinoma as compared with adenoma and normal mucosa. Int J Cancer 1999; 83:579-584.
22. Lee W-P, Liao Y, Robinson D, Kung H-J, Liu ET, Hung M-C. Axl-Gas 6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activtiy. Mol Cell Biol 1999; 19:8075-8082.
23. Meric F, Lee W-P, Sahin A, Zhang H, Kung H-J, Hung M-C. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002; 8:361-367.
24. Quong RYY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and transformed melanocytes. Melanoma Res 1994; 4:313-319.
25. Lin J-S, Lu C-W, Huang C-J, Wu P-F, Robinson D, Kung H-J, et al. Proteintyrosine kinase and protein-serine/trhreonine kinase expression in human gastric cancer cell lines. J Biomed Sci 1996; 5:101-110.
26. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa H. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997; 65:195-203.
27. Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol 1993; 101:679-684.
28. Shelly S, Chien MB, Yip B, Kent MS, Theon AP, McCallan JL, London CA. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mamm Genome 2005; 16:211-217.
29. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, et al. C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 2003; 20:421-430.
30. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004; 92:77-91.
31. Zavodovskaya R, Liao AT, Jones CL, Yip B, Chien MB, Moore PF, London CA. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res 2006; 67:633-641.
32. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999; 27:689-697.
33. London CA, Kisseberth WC, Galli SJ, Geissler EN, Helfand SC. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 1996; 115:399-414.
34. Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004; 84:562-572.
35. Yonemaru K, Sakai H, Murakami M, Yanai T, Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Vet Pathol 2006; 43:971-980.
36. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43:1-8.
37. Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000; 17:193-202.
38. Kanter-Lewensohn L, Dricu A, Wang M, Wejde J, Kiessling R, Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res 1998; 8:389-397.
39. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of insulinlike growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: an immunohistochemical study. Curr Eye Res 2006; 31:875-883.
40. Furlanetto RW, Harwell SE, Baggs RB. Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice. Cancer Res 1993; 53:2522-2526.
41. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54:4848-4850.
42. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001; 61:7318-7324.
43. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:2337-2342.
44. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2008; 128:1499-1505.
45. Neudauer CL, McCarthy JB. Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellularregulated kinase activation. Exp Cell Res 2003; 286:128-137.
46. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ 2002; 13:87-93.
47. Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 1989; 264:21544-21549.
48. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI, Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001; 20:4029-4040.
49. Yeh AH, Bohula EA, Macaulay VM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006; 25:6574-6581.
50. Girnita A, All-Ericsson C, Economou MA, Astrom K, Axelson M, Seregard S, et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 2006; 12:1383-1391.
51. Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004; 54:25-33.
52. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002; 100:585-593.
53. Liao AT, McCleese J, Kamerling S, Christensen J, London CA. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol 2007; 5:177-196.
54. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008; 22:985-988.
55. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003; 9:2755-2768.
56. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003; 9:5729-5734.
57. Hahn KA, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22:1301-1309.
58. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15:3856-3865.